Autopsy report · NCT01517776

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“due to an altered benefit/risk assessment.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 2 years 3 months before it stopped.
28 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor type: University, hospital or other
Conditions: Gliomas
Interventions: Cilengitide; Temozolomide
Participants: 28
Sites: 1
Countries: Germany

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.